Recent studies, including our own unpublished work, have shown that GLUT3 can bind to and influence the uptake of chemotherapeutic agents like gemcitabine, enhancing chemotherapy sensitivity of triple-negative breast cancer cells. Here, SLC2A3 is linked to triple-negative breast carcinoma.